Review

Autologous Cord Blood in Children with Cerebral Palsy: A Review

Dariusz Boruczkowski 1,*, Josep-Maria Pujal 2 and Izabela Zdolińska-Malinowska 1

1 Polski Bank Komórek Macierzystych S.A. (FamiCord Group), Jana Pawła II 29, 00-867 Warsaw, Poland; izabela.zdolina-malinowska@pbkm.pl
2 Sevibe Cells, Parc Científic i Tecnologic de la UdG, C/Pic de Peguera No. 11, 17003 Girona, Spain; jmpujal@sevibe.es
* Correspondence: dariusz.boruczkowski@pbkm.pl; Tel.: +48-608-200-777

Received: 26 March 2019; Accepted: 12 May 2019; Published: 16 May 2019

Abstract: The aim of this narrative review is to report on the current knowledge regarding the clinical use of umbilical cord blood (CB) based on articles from PubMed and clinical trials registered on ClinicalTrials.gov. An increasing amount of evidence suggests that CB may be used for both early diagnostics and treatment of cerebral palsy. The acidity of CB and its biochemical parameters, including dozens of cytokines, growth factors, and other metabolites (such as amino acids, acylcarnitines, phosphatidylcholines, succinate, glycerol, 3-hydroxybutyrate, and O-phosphocholine) are predictors of future neurodevelopment. In addition, several clinical studies confirmed the safety and efficacy of CB administration in both autologous and allogeneic models, including a meta-analysis of five clinical trials involving a total of 328 participants. Currently, nine clinical trials assessing the use of autologous umbilical CB in children diagnosed with hypoxic-ischemic encephalopathy or cerebral palsy are in progress. The total population assessed in these trials exceeds 2500 patients.

Keywords: cord blood; stem cells; cellular therapy; cerebral palsy; hypoxia; hypoxic-ischemic encephalopathy; HIE; ischemia; perinatal brain injury; asphyxia

1. Introduction

The etiology of 70% of cerebral palsy (CP) cases remains unknown. In 20% of children, it may be associated with prematurity, perinatal trauma, or brain hypoxia. Other [specific] causes include infections and defects that arise during fetal life. According to different authors, the frequency of CP is 1.24–3.8/1000 live-born children [1]. The diagnosis of CP is based on a carefully collected medical history, but early diagnosis may be difficult in children with minor alterations. In particular, early diagnosis is important in children with no aggravated perinatal history, as it allows an early start of therapy, especially with stem cells. Cord blood (CB) has been successfully used in CP in both auto-[2–4] and allogeneic [5,6] administrations. Animal studies have shown that the timing of stem cell administration is crucial for the effectiveness of CP therapy [7] and suggest that results may also be time-dependent in humans. Therefore, many scientists seek biochemical predictors of CP in CB. The long-term diagnostic value of CB is well-established. In fact, it has been shown that approximately 90 CB proteins are predictors of disorders diagnosed in adults, such as cancer and cardiovascular, neurodegenerative, infectious, and metabolic diseases [8]. A meta-analysis of 51 articles, including over 481,000 children, showed that CB acidity was significantly associated with neonatal mortality (odds ratio [OR] 16.9), hypoxic-ischemic encephalopathy (HIE) (OR 13.8), intraventricular hemorrhage or periventricular leukomalacia (OR 2.9), cerebral palsy (OR 2.3) [9], and the overall incidence of neonatal complications [10]. Other predictive factors for CP are two clusters of 33 cytokines and growth factors [11]. Only one variable—an interleukin (IL)-16 level ≥ 514 pg/mL—predicted a severe
outcome, with a sensitivity of 83% and a specificity of 81% [12]. A metabolomic analysis by Walsh et al. showed a significant increase in 29 out of the 148 metabolites (amino acids, acylcarnitines, and phosphatidylcholines) measured in the umbilical CB of infants with either asphyxia or HIE compared to matched healthy controls [13]. A similar study by Ahearne et al. indicated that succinate, glycerol, 3-hydroxybutyrate, and O-phosphocholine levels can also predict the three-year neurodevelopmental outcome in infants with perinatal asphyxia and HIE [14]. CB analysis may also retrospectively explain unexpected clinical outcomes. For instance, a suboptimal concentration of antioxidative micronutrients and heavy metal overload in CB, as well as alterations in DNA methylation in both placenta and CB, are associated with preterm birth [15,16].

2. The Scientific Basis for the Use of Umbilical Cord Blood in the Treatment of Cerebral Palsy

2.1. Cord Blood Composition and Its Mode of Action

CB contains, among other components, stem cells, anti-inflammatory cytokines, and—to a lesser extent—proinflammatory cytokines. The following cell populations have potential neuroregenerative properties: Umbilical CB-derived mesenchymal stem cells (CB-MSCs); umbilical CB-derived unrestricted somatic stem cells (CB-USSCs); umbilical cord-derived embryonic-like stem cells (CB-CBEs); umbilical CB-derived multipotent progenitor cells (CB-MPCs); umbilical CB-derived endothelial progenitor cells (CB-EPCs); umbilical CB-derived T regulatory cells (CB-Tregs); umbilical vein MSCs (CB-MDSCs); and Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) [17,18]. CB cells secrete immunomodulatory and neurotrophic factors that can contribute to central nervous system (CNS) repair [19]. Therefore, the suggested mechanisms for the neuroprotective effect of CB stem cells include neural differentiation, anti-apoptotic and anti-inflammatory actions, the stimulation of angiogenesis, and the production of trophic factors [20,21]. The mode of action depends on the disease [22] and may be multidirectional.

2.1.1. Homing and Neurodifferentiation

The in vitro differentiation of human CB-MSCs into neural cells has been confirmed [23,24] and some studies suggest that these cells can cross the blood-brain barrier like leukocytes [25]. Stem cell homing is a complex process that starts with the migration of the activated stem cells along the concentration gradient and ends with the fulfillment of their regenerative functions [26]. Cell migration begins with the adhesion of the cells to the vascular endothelium at the target tissue and the binding of their homing receptors, followed by extravasation [27]. It is regulated by extracellular growth factors, chemokines, and microRNA [28]. The stromal cell-derived factor 1 (SDF-1) is a chemokine thought to influence human umbilical CB (hUCB) cell migration. SDF-1 is expressed in many tissues, but its expression is increased in the brain after hypoxic-ischemic injury, mainly on the astrocytes and glial cells of the injured hemisphere [29–31]. Transplanted hUCB cells expressing the SDF-1 receptor CXCR4 have been observed to migrate to the site of injury within 24 h [32].

After homing, stem cells engage in paracrine signaling to induce target cells to initiate progenitor cell proliferation and tissue repair. Stem cell paracrine activity, their most important therapeutic mechanism, is characterized by the secretion of extracellular vesicles (EVs) and soluble factors. Some of the soluble factors have been proposed for adjuvant stem cell therapy, including granulocyte colony stimulating factor (GCSF), brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), and glial cell line-derived neurotrophic factor (GDNF) (Table 1). In particular, BDNF, GDNF, and GCSF are involved in the development, regeneration, and survival of neurons [33–37]. In a rodent model of HIE, MSCs exerted neuroprotective effects by enhancing autophagy through the BDNF/mTOR signaling pathway [38]. GCSF activates STAT proteins and the PI3-K/Akt pathway [39]. Results from non-stroke studies indicate that BDNF affects differentiating oligodendrocytes and improves axonal growth and plasticity by increasing the levels of MBP cells and MBP protein and decreasing Nogo-A levels [34]. In vitro studies show that GPE, the N-terminal tripeptide of the insulin-like growth
factor 1 (IGF-1), stimulates neural stem cell proliferation and migration by activating the extracellular signal-regulated kinase (ERK) and PI3K-Akt pathways [40]. The Akt pathway is activated by the endogenous recombinant prion protein [41] that is mainly expressed in the central and peripheral nervous system [42].

Table 1. Neuroprotective properties of growth factors proposed for adjuvant stem cell therapy.

| Cell Targets | Effect |
|--------------|--------|
| BDNF | ↑ proliferation and differentiation of oligodendrocyte precursor cells [34] |
| EGF | ↑ survival, proliferation, and migration of neural precursor cells [37] |
| GCSF | ↑ neurogenesis [46] |
| GDNF | ↑ differentiation of neural precursor cells into astrocytes [47,48] |
| IGF-1 | ↑ neural stem cell proliferation and migration [42] |

Table 2. Effects of extracellular vesicle administration in specific diseases.

| Disease | Effect |
|---------|--------|
| Stroke [59] | ↑ synaptogenesis, ↑ angiogenesis, ↓ apoptosis |
| Traumatic brain injury [58] | ↓ inflammation-induced neuronal degeneration, ↓ microgliosis, ↓ astrogliosis |
| Parkinson’s disease [60] | ↓ apoptosis |
| Alzheimer’s disease [61] | neprrlysin secretion |
| Autism [62] | ↓ autisitic behaviors |
| Hepatic ischemia [50] | ↓ necrosis, ↓ apoptosis, ↓ inflammation, ↓ oxidative stress |
| Hepatic failure [51] | ↓ apoptosis, ↓ inflammation |
| Myocardial infarction [53] | ↑ neovascularization, ↓ inflammation |
| Myocardial hypoxia [54] | ↑ Wnt/β-catenin signaling pathway (↑ survival, ↓ apoptosis) |
| Ischemic-hypoxic kidney injury [55,56] | ↓ apoptosis, ↓ inflammation, ↑ proliferation, ↑ function, ↓ CX3CL1, ↓ CD68+ |

2.1.2. Extracellular Vesicles

In recent years, the interest of scientists in the role of extracellular vesicles (EVs)—micro- or nanoparticles carrying mRNA, microRNA, and proteins [49]—has grown. EVs were effective in the treatment of animal models of liver diseases [50–52], myocardial infarction [53], myocardial hypoxia [54], ischemic-hypoxic kidney injury [55,56], inflammation-induced preterm brain injury [57], traumatic brain injury [58], stroke [59], Parkinson’s disease [60], Alzheimer’s disease [61], and autism [62] (Table 2). They easily cross the blood-brain barrier [63] and accumulate in pathologically relevant brain regions through an inflammation-driven mechanism [64]. MSC-EV administration improves brain function and inflammation-induced neuronal degeneration, inhibits intracerebral inflammation, reduces microglial proliferation, prevents reactive astrocyte proliferation, and improves spatial learning impairments [62]. Short-term myelin deficiency and long-term white matter microstructural abnormalities ameliorated after administration of MSC-EVs [65]. Recently, Lin et al. developed a platform for the neural differentiation of induced pluripotent stem cells (iPSCs), which consisted of polybutylcyanoacrylate nanoparticles with either surface-adsorbed BDNF or encapsulated BDNF. Both methods effectively induced neural differentiation [66].

Table 2. Effects of extracellular vesicle administration in specific diseases.
2.1.3. Tunnelling

A tunnelling phenomenon has been described in MSC populations, involving the exchange of molecules and organelles such as calcium ions, prions, viral and bacterial pathogens, small lysosomes and mitochondria [67]. However, whether it is relevant in CP is unknown.

2.2. Efficacy of MSC Administration in Animal Models of Hypoxia

The effectiveness of CB in CP treatment has been repeatedly tested in animal models. In 2006, Meier et al. intraperitoneally administered CB mononuclear cells to rats that had been previously subjected to ischemia by ligation of the carotid artery and showed symptoms of contralateral spastic paralysis. Most of the neurological symptoms were alleviated in the examined animals [68]. In another study, also conducted in a rat model of neonatal hypoxia/ischemia, intravenously administered CB cells transiently increased the activity of microglia in the striatum and had a protective impact on mature neurons of the new cortex, which significantly improved the motor test results of the study group. The results persisted three weeks after the infusion, although in most cases, the presence of the administered cells was not detected in the CNS [69]. Zhang et al. [70] transplanted labeled UC-MSCs and CB mononuclear cells (MNCs) into rats with hypoxia-ischemia (HI)-induced brain damage. They reported reduced astrogliosis, prevention of neuronal loss in the striatum, and a marked improvement in functional brain outcomes after a 28-day recovery period. In addition, treatment with CB-MNCs increased the proportion of mature oligodendrocytes and improved myelination in the cortex. Similar neuroprotective results were obtained by Li et al. in a preterm sheep model of white matter injury. They reported that infusions of UCB-derived MSCs administered after hypoxia-ischemia in the preterm brain reduced white matter injury by inhibiting microglial activation and the release of TNFα, promoting macrophage migration, and accelerating self-repair [71]. In neonatal rats with intraventricular hemorrhage, hUCB-MSCs attenuated neuronal loss and promoted neurogenesis in the hippocampus, which is essential for learning, memory, and cognitive functions. These stem cells also contributed to the restoration of impaired synaptic circuits in the hippocampus, leading to the improvement of neurocognitive functions in these animals through BDNF-TrkB-CREB signaling axis activation [72]. This may explain the improvement in these skills observed in children with CP after WJ-MSC administration [73].

The immunomodulatory properties of T regulatory cells (Tregs) and monocyte-derived suppressor cells (MDSCs) was confirmed by McDonald et al. in the mouse model [74]. In this study, infiltration of CD4+ T cells into the injured cerebral hemisphere was significantly reduced by all hUCB cell types evaluated. However, Tregs and EPCs additionally reduced motor deficits, CD4+ T cell infiltration into the brain, and microglial activation. EPCs also significantly reduced cortical cell death and the peripheral Th1-mediated proinflammatory shift, and they returned CD4+ T cell infiltration to sham levels. In a sheep model, human CB reduced white matter cell death and inflammation and recovered total and mature oligodendrocytes [75]. In a rat model, human CB reduced astrogliosis, prevented neuronal cell loss in the striatum, and improved functional brain outcomes. Additionally, CB mononuclear cells increased the proportion of mature oligodendrocytes and improved myelination in the cortex [70].

The paracrine interaction mechanism was confirmed by the preclinical study conducted by Drobyshevsky et al., in which intravenous administration of a large CB dose changed the natural course of hypoxic-ischemic damage in the tested animals. Magnetic resonance imaging (MRI) examination of the CNS showed little penetration of labeled cells, which may suggest a paracrine effect [76]. CB can also be effective in the treatment of neurological deficits caused by intraventricular bleeding [77] or traumatic CNS injury [78].
2.3. The Influence of Low Oxygen Concentration on Stem Cells

Zhao et al. provided interesting findings concerning the use of autologous CB after hypoxia. They found that when CB CD34+ cells were co-cultured with WJ-MSCs, a physiological low oxygen concentration (1% O2) was better for the maintenance of stem cell traits than normal oxygen conditions [79]. The cultures exposed to low oxygen concentration had higher percentages of CD34+ Lin− cells and long-term culture-initiating cells. Low oxygen resulted in an increased secretion of vascular endothelial growth factor and a decreased secretion of interleukin (IL)-6, IL-7, stem cell factor, and thrombopoietin by WJ-MSCs. Low oxygen also resulted in the activation of stem cell signaling pathways in the CB stem/progenitor cells. Thus, oxygen concentration may be a tool with important clinical implications. Zhang et al. [80] showed that BM-MSCs cultured at a low (1%) oxygen concentration also displayed greater proliferative potential and reduced apoptosis. The administration of hypoxia-preconditioned MSCs decreased ischemia/reperfusion injury by attenuating inflammatory responses associated with the generation of reactive oxygen species [81]. The influence of oxygen concentration on stem cell properties was recently reviewed by Mas-Bargues et al. [82].

3. Clinical Trials Assessing the Use of Autologous Umbilical Cord Blood in the Treatment of Cerebral Palsy

Autologous CB has been used worldwide in transplantology [83,84], hematology [85], cardiac surgery [86], and endocrinology [87,88]. Among other neurological diseases, auto-CB has been used in Duchenne muscular dystrophy [89,90], cerebral palsy [91], and autism spectrum disorder [92,93]. Current studies are exploring the use of umbilical CB in the treatment of HIE (Table 3), congenital hydrocephalus, traumatic brain injury, ischemic stroke, global developmental delay, and ataxia. Autologous peripheral blood was confirmed to be safe and effective in children with cerebral palsy in a double-blind, placebo-controlled trial in 2017 [33].

**Table 3.** Current clinical trials assessing the use of cord blood in children diagnosed with hypoxic-ischemic encephalopathy or cerebral palsy.

| ClinicalTrials.gov ID | Therapy | Sample Size (n) | Phase | Status on 18 January 2019 |
|-----------------------|---------|----------------|-------|--------------------------|
| NCT02881970           | Autologous cord blood         | 20     | I, II          | Not yet recruiting       |
| NCT02551003           | Autologous cord blood + hypothermia | 60     | I, II         | Recruiting               |
| NCT03352310           | Autologous cord blood         | 40     | I             | Recruiting               |
| NCT02434965           | Autologous cord blood and human placenta-derived stem cells | 20     | II            | Not yet recruiting       |
| NCT02612155           | Autologous cord blood         | 160    | II            | Recruiting               |
| NCT03123081           | Umbilical cord milking        | 400    | NS            | Not yet recruiting       |
| NCT03682042           | Umbilical cord milking        | 350    | NS            | Not yet recruiting       |
| NCT03657394           | Umbilical cord milking        | 1400   | III           | Not yet recruiting       |
| NCT01072370           | Autologous cord blood         | 40     | I, II         | Recruiting               |
| NCT03791372           | Autologous umbilical cord blood mononuclear cells | 25     | I             | Recruiting               |
| NCT03327467           | Autologous or sibling cord blood | NS     | NS            | Available                |

NS—not specified.

3.1. Early Phase Clinical Studies

Cotten et al. tested the feasibility and safety of providing non-cryopreserved autologous volume- and red blood cell-reduced umbilical CB cells to neonates with HIE and concluded that this procedure is possible, safe, and should be verified in clinical trials [94]. After administration of the same cell fraction, Yang et al. [95] and Kotowski et al. [96] obtained the same results in preterm newborns and very premature neonates, respectively. Additionally, Kotowski confirmed a significant increase of 22 plasma proteins (e.g., insulin-like growth factors, stem cell factor, epidermal growth factors) in
recipients of autologous umbilical CB and a decreased percentage of intraventricular hemorrhages in the treated group (40% vs. 86.7%).

In a study by Lee et al. [97], autologous umbilical CB was administrated intravenously to 20 patients diagnosed with CP at the age of 2–10 years [mean 55 months]. An average of $5.5 \pm 3.8 \times 10^7 [0.6–15.65]$ total nucleated cells (TNC)/kg of body weight was given. Three patients experienced transient nausea and hemoglobinuria, and the next two patients had hemoglobinuria and urticaria, which disappeared after antihistamine treatment and intravenous hydration. The motor skills and cognitive functions of the patients were evaluated after six months. It was estimated that there was a noticeable improvement in 14 out of 20 patients and that five patients were significantly better than would be expected after standard care for CP. Patients with quadriplegia responded to treatment the worst. MRI track-density imaging (MRI-TDI) and single photon emission computed tomography (SPECT) were also performed, and the results seemed to correlate partially with clinical improvement.

In 2015, a research group at Duke University [98] announced the first results from a randomized, double-blind, crossover trial on CP treatment with autologous CB. The study involved 63 patients with a median age of two years. The target TNC doses were $1–5 \times 10^7$/kg, the final TNC median dose was $2 \times 10^7$/kg [0.4–5], the median CD34+ cell dose was $0.5 \times 10^5$/kg [0.05–4]. After the infusion, patients were monitored for 2–4 h. One patient had urticaria and mild fever. The motor assessment of patients one year after administration did not show statistically significant differences between the study and control groups, but a significant difference was found between the group that received infusions with TNC doses $>2.5 \times 10^7$/kg and the group that received lower doses. The group of patients treated with higher cell doses experienced an improvement in motor skills.

The same research group published the results of an MRI study on 17 children who took part in the clinical trial described above and experienced a clinical improvement. A strong correlation was found between the increase of white matter integrity and the functional improvement of the patients [99]. In 2017, the same research team published the results of a double-blind, placebo-controlled study on the effects of a single intravenous infusion containing $1–5 \times 10^7$ TNC/kg from autologous umbilical CB in children with CP up to six years of age [91]. Motor skills and brain MRI studies were performed at the beginning of the study and one and two years after treatment. Sixty-three children (median age of 2.1 years) were randomly assigned to the treatment group ($n = 32$) or to the placebo group ($n = 31$) at the beginning of the study. Although there was no significant difference in the results between the treatment and placebo groups after one year, a therapeutic effect that was dependent on the number of cells administered to the patients was identified. One year after autologous treatment, the children who received a dose greater than $2 \times 10^7$ cells/kg showed a significantly greater improvement on several scales. The results of this study suggest that a properly administered infusion of autologous umbilical CB improves brain function and some motor functions in young children with CP.

Xie et al. reported that in adult patients with HIE, human umbilical cord (hUC)-MSC transplantation was safe and resulted in a significant improvement regarding recovery of neurological function, cognition ability, emotional reaction, and extrapyramidal function [100]. The results were evaluated using several clinical assessment scales, and no significant adverse events were reported during the 180-day follow-up period.

Huang et al. [101] conducted a randomized, placebo-controlled trial on the use of MSCs from human umbilical CB (hCB-MSC) in 54 children with CP. It was a two-arm study in which, along with basic rehabilitation, one arm received intravenous hCB-MSC infusions at a fixed dose of $5 \times 10^7$ cells/kg, and the other received 0.9% normal saline. The endpoints were assessed during the study and during 24 months of follow-up and were the following: Gross Motor Function Measure (GMFM-88), a comprehensive functional assessment (CFA), lab tests, electroencephalogram (EEG), routine MRI, and adverse events. The changes in the total proportion of GMFM-88 and the total CFA scores in the hCB-MSC infusion group were significantly higher than those in the control group three, six, 12, and 24 months after administration. Patients with slowing EEG background rhythms at baseline had less diffused slow waves after hCB-MSC administration. Improvements in cerebral structures as observed
by MRI were rare. No serious adverse events were noticed. The authors concluded that hCB-MSC infusion with basic rehabilitation was safe and effective at improving gross motor and comprehensive functions in children with CP.

Bae et al. compared the intravenous application of autologous CB with that of allogeneic CB with a four out of six human leukocyte antigen (HLA) match [102]. In this study, both the safety and efficacy of umbilical CB administration were evaluated. The study group consisted of seven patients with a mean age of 38 weeks. Three patients received allogeneic cells and four received autologous cells. The patients also received erythropoietin 12 h prior to CB administration. The patients in the allogeneic group \( n = 3 \) received cyclosporine at a dose of 15 mg/kg before transplantation and for six days after transplantation. For the next three weeks, they received a reduced dose of 10 mg/kg. The group of patients who received allogeneic CB had significantly lower levels of proinflammatory cytokines, such as IL-1beta, tumor necrosis factor-beta, IL-6, and RANTES. In the autologous group, the level of proinflammatory cytokines significantly increased after transplantation. Only the allogeneic group experienced a significant improvement in gross motor performance and social skills. The study was conducted only on seven patients, and the average birth age of the examined children in both groups was significantly different, which could influence the results. To date, no larger study has been published.

### 3.2. Safety

In cases of intravenous CB infusion in children with CP, fever, nausea, urticaria, hemoglobinuria, increase in blood pressure, and transient decreases in saturation were observed. During the infusion of a blood product, there may be early and late complications. Early complications include nonhemolytic transfusion reactions (such as chills and fever), urticaria, anaphylactic shock, septic shock caused by bacterial infection of the CB unit, transfusion-related acute lung injury, air embolism, acute pain during transfusion, and hypocalcemia associated with transfusion of a CB unit containing citrate. Late complications include, first, transfusion-associated graft versus host disease. In addition, a single transfusion containing an excessive amount of cryoprotective agent can cause dimethyl sulfoxide poisoning (e.g., in the form of neurotoxicity). Infection transmission from non-tested or non-diagnosed infectious agents (e.g., prions) can also occur. However, the risk of such infection is reduced by having access to the mother’s accurate medical history before collecting the CB.

A meta-analysis regarding the safety and efficacy of cellular therapies [103] showed that serious adverse events occurred rarely, only in four out of 135 people in the study groups and in three out of 139 people in the control groups. This meta-analysis covered clinical trials related to umbilical CB and other cells, such as olfactory and nerve cells and nerve cell progenitors.

In 2015, Feng et al. [104] published a retrospective study regarding the safety of the intravenous/intrathecal therapeutic administration of stem cells derived from CB. Forty-seven patients with CP with a median age of 5.85 ± 6.12 years (1–29 years) received an average of 2–3 \( \times 10^7 \) CB cells. The number of applications was determined depending on whether side effects occurred, with a minimum of four infusions and a maximum of eight infusions, and the interval between infusions was three to five days. No serious adverse events occurred, although mild ones were observed quite often (in 26 patients) and were mostly fever (42.6%) or vomiting (21.2%). Intrathecal infusion and the ages at the initiation of treatment (\( \leq 10 \) years old) were associated with increased risk of adverse events. It could be associated with the relatively large dose of cells given in relation to the patients’ weight. All adverse events were treated with symptomatic treatment. The follow-up period lasted six months. The treatment procedure was stated as safe, although no immunosuppressive treatment was used and there was no full HLA match between recipient and donor.

Sun et al. [105] demonstrated the safety of multiple infusions of intravenous autologous umbilical CB in children with congenital hydrocephalus. In a study lasting more than 18 years, 76 patients received 143 infusions of autologous CB, including 45 patients who received two infusions, 18 patients who received three, and four patients who received four. There were no infusion-related adverse
events. The median age of the treated children was two years (six days–4.5 years). Five CB units had a positive result for bacterial infection after thawing (an earlier result was negative), which were available 24–72 h after the infusion, but the patients did not present clinical symptoms and were not treated with antibiotics. The patients were premedicated with paracetamol (10 mg/kg) and diphenhydramine (0.5 mg/kg) administered orally and methylprednisolone (0.5 mg/kg) administered intravenously. An average of $1.9 \times 10^7$ TNC/kg ($0.1$–$13.3 \times 10^7$ TNC/kg) and $0.5 \times 10^5$ ($0$–$6.4 \times 10^5$) CD34+ cells/kg were administered.

4. Past and Future Perspectives

Almost 10 years ago, Hadar Arien-Zakay et al. [106] summarized 20 years of CB use, highlighting several issues for future studies. These issues included identifying the preferred cell population, investigating the efficacy of a single CB unit administration for ischemic brain therapy and the possibility of the in vitro expansion of CB-derived cells before transplantation, measuring the significance of the biological differences intrinsic to individual units of CB on the reproducibility of results, and identifying the therapeutic time window. The studies conducted in the last decade have not answered all these questions. Jin [107] showed that UCB-MSCs had the highest rate of cell proliferation and clonality and significantly lowered markers of senescence, compared with bone marrow (BM) and adipose tissue-derived stem cells. However, these results were observed in animals and have not been confirmed in clinical studies, despite arguments confirming their predominance [108]. Some studies have confirmed the superiority of UC-MSCs over BM in terms of secreteme [109] and migration speed [110]. An evaluation of the expression of 106 cytokines between UCB-derived and UC-derived MSCs showed differences in the excretion of the following: TSP-1, TSG-14, TIMP-1, IL-8, IL-6, CXCL1, GIF, and IGFBP3. The expression of CCL2 in UC-MSCs was significantly higher than in CB-MSCs, whereas the secretion of IGFBP1 and IGFBP2 by CB-MSCs was higher than by UC-MSCs [111]. This suggests that UC-MSCs and CB-MSCs differ in their functional potentials, which must be carefully considered before clinical treatment. Nevertheless, a recent study in an equine model showed that CB-MSCs have a greater differentiation potential and similar immunosuppressive potential as WJ-MSCs [112]. Data for human cells are still unavailable. On the other hand, DNA methylation in CB and UC differs in human neonates [113]. Therefore, the identification of the best cell population is still an unsolved issue, as is the question regarding the most effective fractions of UCB.

The efficacy of a single CB unit administration was confirmed in children under 10 [97]. A technique of the ex vivo expansion of CB-derived stem cells has been developed, and its clinical efficacy has been positively verified, despite initial problems [114–118]. However, the cells expanded ex vivo undergo changes in genetic expression, which is an issue that requires further studies [119]. Additionally, the parameters of CB units may be ameliorated by improving the CB thawing procedure [120], using DMSO dextrose instead of DMSO [121], and adding new substances before cryopreservation, such as quercetin [122].

The time window for successful therapy has not been established. In a study assessing the efficacy of G-CSF with or without autologous peripheral blood stem cells in children with CP, responders and non-responders did not differ in age, but they were preschoolers ($3.2 \pm 1.5, 4.7 \pm 1.9, p = 0.968$) [33]. In adults with ischemic stroke, the infusion of a single allogeneic CB unit was enough to obtain a sustained therapeutic effect [123].

In our opinion, besides the issues mentioned above, the most interesting questions for future studies concern the interactions between different types of stem cells and the clinical efficacy of cell therapies combined with substances approved for other indications. The anti-senescent properties of some of these substances may also be a promising strategy to increase the number of passages in stem cell cultures. For instance, although polyunsaturated fatty acids have no influence on CB cytokines, the impact of other CB parameters and clinical outcomes after therapeutic applications of CB is unknown [124]. Resveratrol induced the differentiation of hUC-MSC into neuron-like cells [125], improved hUC-MSC repair in cisplatin-induced acute kidney injury [126], prevented cellular damages
induced by monocrotophos via the PI3K signaling pathway in human CB-MSCs [127], and promoted hUC-MSC engraftment and neural repair in a mouse model of Alzheimer’s disease [128]. Quercetin has multiple effects (Table 4). It enhanced the differentiation of BM-MSCs into bone cells in rat [129] and mice models [130]. In vitro, quercetin promoted the differentiation of BM-MSCs into β-cells with increased insulin secretion [131]. In a rat model of spinal injury, a combination therapy including quercetin and hUC-MSCs improved the neurological functional recovery, increased axonal preservation, promoted macrophage polarization, decreased the size of the cystic cavity, reduced the proinflammatory cytokines, and increased anti-inflammatory cytokines compared with hUC-MSCs alone [132]. In human BM cell cultures, quercetin inhibited osteogenetic differentiation and promoted adipogenesis [133]. On the other hand, it stimulated hepatic differentiation and increased cell viability and resistance to oxidative stress [134]. The use of quercetin in rat BM-MSC cultures improved cell proliferation and angiogenic factor secretion in a dose-dependent manner [135]. Quercetin induced cell death in cultures of undifferentiated human pluripotent stem cells (hPSCs) but not human dermal fibroblasts, suggesting it may decrease the risk of teratoma formation during hPSC-based cell therapy [136]. It also exhibited genotoxic effects in human hematopoietic stem and progenitor cells when applied continuously and at high concentrations [137]. Baral et al. investigated the effects of quercetin on neurodifferentiation and stem cell migration, but their results were inconclusive. Although quercetin increased differentiation and migration, it also decreased cell viability [138]. Apigenin increased the expression of neuronal markers and the number of neural progenitor cells obtained from human embryonic stem cells and human iPSCs [139]. Luteolin affected the pro-inflammatory secretion activity of human mast cells [140]. Apigenin and luteolin promoted human hematopoietic stem cell differentiation [141] and were confirmed safe for developing vertebrates in terms of neurobehavior [142].

**Table 4.** Positive and negative effects of quercetin on mesenchymal stem cells.

| Parameter                  | Effect          | Model                                                                 |
|----------------------------|-----------------|----------------------------------------------------------------------|
| Proliferation              | Increased       | Rat BM-MSC cultures [135] Mice BM-MSC cultures [130]                |
| Viability                  | Increased       | Human BM cell cultures [134]                                         |
|                            | Decreased       | hPSCs [140], hHSC, and progenitors [137], human embryonic NSCs culture [138] |
| Migration                  | Increased       | Human embryonic NSCs culture [138]                                  |
| Resistance to oxidative stress |                | Human BM cell cultures [134]                                        |
| Differentiation            |                 |                                                                     |
| into neural cells          | Increased       | Human embryonic NSCs culture [138]                                  |
| into bone cells            |                 |                                                                     |
|                            | Increased       | Rat BM-MSCs cultures [129], mice BM-MSC cultures [130]              |
|                            | Decreased       | Human BM cell cultures [133]                                        |
| into β-cells               | Increased       | Rat BM-MSC cultures [131]                                           |
| into hepatic cells         | Increased       | Human BM cell cultures [134]                                        |
| into fat tissue cells      | Increased       | Human BM cell cultures [133]                                        |
| Proinflammatory cytokines  | Decreased       | Rat model of spinal cord injury [132]                               |
| Anti-inflammatory cytokines| Increased       | Rat model of spinal cord injury [132]                               |
| Angiogenic factor secretion| Increased       | Rat BM-MSC cultures [135]                                           |
| BDNF secretion             | Increased       | Human embryonic NSCs culture [138]                                  |

BDNF: Brain-derived neurotrophic factor, BM: Bone marrow, hHSC: Human hematopoietic stem cells, MSC: Mesenchymal stem cells, NSC: Neural stem cells, hPSCs: Human pluripotent stem cells.

Studies investigating the mutual interactions between stem cell subpopulations are also in their infancy. It has been shown that CB hematopoietic progenitors influence the expression of genes
encoding for adhesion molecules and molecules of the connective tissue matrix [143]. Its remodeling enzymes was also studied in multipotent mesenchymal stromal cells (MSCs) from human adipose tissue [144]. In a direct cell-cell contact culture system, WJ-MSCs enhanced the expansion of CB-CD34+ cells [145]. Further investigations in this field are required.

5. Conclusions

Stem cell therapy is a promising area for future investigations and clinical applications. According to currently available knowledge, it seems to be a safe and effective treatment that can significantly improve functioning in children with CP, although a complete recovery is unlikely. However, due to the severe consequences of this disease and the lack of causal treatment, stem cell therapy remains the main hope for the improvement of these patients’ condition, especially concerning cognitive functions.

Author Contributions: Conceptualization, D.B., J.-M.P., and I.Z.-M.; Methodology, Software, Validation, Data Curation, Formal Analysis, and Visualization: N/A; Investigation & Resources, D.B., I.Z.-M.; Writing—Original Draft Preparation, D.B., I.Z.-M.; Writing—Review & Editing, J.-M.P.; Supervision, D.B. and J.-M.P.; Project Administration & Funding Acquisition, N/A.

Funding: This research received no external funding.

Acknowledgments: Language assistance was provided by Marisa Granados.

Conflicts of Interest: D.B. and I.Z.-M. are employees of Polski Bank Komórek Macierzystych S.A. (FamiCord Group), Warsaw, Poland. The paper has been written as part of their professional duties. However, the sponsor had no role in the design, execution, interpretation, or writing of the manuscript except the acceptance of the final version. J.-M.P. is an employee of Sevibe Cells, which is the capital subsidiary of Polski Bank Komórek Macierzystych S.A, Warsaw, Poland. The authors declare no other conflict of interest.

Abbreviations

| Acronym | Full Form | Description |
|---------|-----------|-------------|
| BDNF | brain-derived neutrophic factor | |
| BM | bone marrow | |
| CB | cord blood | |
| CNS | central nervous system | |
| CP | cerebral palsy | |
| EEG | Electroencephalography | |
| EPC | endothelial progenitor cells | |
| EV | extracellular vesicles | |
| GCSF | granulocyte colony stimulating factor | |
| GMFM-88 | Gross Motor Function Measure | |
| HIE | hypoxic-ischemic encephalopathy | |
| HLA | human leukocyte antigen | |
| hUCB | human umbilical cord blood | |
| MDSC | monocyte-derived suppressor cells | |
| MRI | magnetic resonance imaging | |
| MSC | mesenchymal stem cell | |
| OR | odds ratio | |
| TNC | total nucleated cells | |
| Treg | regulatory T cells | |
| TrkB | tropomyosin receptor kinase B | |
| UC | umbilical cord | |
| UCB | umbilical cord blood | |
| WJ | Wharton’s jelly | |

References

1. Dunin-Wasowicz, D.; Rowecka-Trzebicka, K.; Milewska-Bobula, B.; Kassur-Siemierska, B.; Bauer, A.; Idzik, M.; Lipka, B.; Marcinski, P. Risk factors for cerebral palsy in very low-birthweight infants in the 1980s and 1990s. J. Child Neurol. 2000, 6, 417–420. [CrossRef] [PubMed]
2. Okur, S.C.; Erdoğan, S.; Demir, C.S.; Günel, G.; Karaöz, E. The Effect of Umbilical Cord-derived Mesenchymal Stem Cell Transplantation in a Patient with Cerebral Palsy: A Case Report. Int. J. Stem Cells 2018, 11, 141–147. [CrossRef]

3. Jensen, A.; Hamelmann, E. First autologous cell therapy of cerebral palsy caused by hypoxic-ischemic brain damage in a child after cardiac arrest-individual treatment with cord blood. Case Rep. Transplant. 2013, 951827. [CrossRef]

4. Papadopoulos, K.I.; Low, S.S.; Aw, T.C.; Chantarajanarsi, T. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor. Neurol. Neurosci. 2011, 29, 17–22. [PubMed]

5. Zhang, C.; Huang, L.; Gu, J.; Zhou, X. Therapy for Cerebral Palsy by Human Umbilical Cord Blood Mesenchymal Stem Cells Transplantation Combined with Basic Rehabilitation Treatment: A Case Report. Glob. Pediatr. Health. 2015. [CrossRef] [PubMed]

6. Jensen, A.; Hamelmann, E. First Autologous Cord Blood Therapy for Pediatric Ischemic Stroke and Cerebral Palsy Caused by Cephalic Molding during Birth: Individual Treatment with Mononuclear Cells. Case Rep. Transplant. 2016, 171426. [CrossRef] [PubMed]

7. McDonald, C.A.; Fahey, M.C.; Jenkin, G.; Miller, S.L. Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options. Pediatr Res. 2018, 83, 333–344. [CrossRef]

8. Hansmeier, N.; Chao, T.C.C.; Goldman, L.R.; Witter, F.R.; Halden, R.U. Prioritization of biomarker targets in human umbilical cord blood: Identification of proteins in infant blood serving as validated biomarkers in adults. Environ. Health Perspect. 2012, 120, 764–769. [CrossRef] [PubMed]

9. Malin, G.L.; Morris, R.K.; Khan, K.S. Strength of association between umbilical cord pH and perinatal and long term outcomes: Systematic review and meta-analysis. BMJ 2010, 340, c1471. [CrossRef] [PubMed]

10. Bao, J.; Liu, J.; Qu, Y.; Mu, D.L. Predictive value of umbilical arterial cord pH on complications during hospitalization in neonates after cesarean section. Beijing Da Xue Xue Bao Yi Xue Ban. 2019, 51, 159–164. [PubMed]

11. Kaukola, T.; Kallankari, H.; Tuimala, J.; Olsén, P.; Tammela, O.; Kingsmore, S.E.; Hallman, M. Perinatal immunoproteins predict the risk of cerebral palsy in preterm children. Ann. Med. 2013, 45, 57–65. [CrossRef]

12. Ahearne, C.E.; Chang, R.Y.; Walsh, B.H.; Boylan, G.B.; Murray, D.M. Cord Blood IL-16 Is Associated with 3-Year Neurodevelopmental Outcomes in Perinatal Asphyxia and Hypoxic-Ischaemic Encephalopathy. Dev. Neurosci. 2017, 39, 59–65. [CrossRef] [PubMed]

13. Walsh, B.H.; Broadhurst, B.I.; Mandal, R.; Wishart, D.S.; Boylan, G.B.; Kenny, L.C.; Murray, D.M. The Metabolomic Profile of Umbilical Cord Blood in Neonatal Hypoxic Ischaemic Encephalopathy. PLoS ONE 2012, 7, e50520. [CrossRef] [PubMed]

14. Ahearne, C.E.; Denihan, N.M.; Walsh, B.H.; Reinke, S.N.; Kenny, L.C.; Boylan, G.B.; Broadhurst, D.I.; Murray, D.M. Early Cord Metabolite Index and Outcome in Perinatal Asphyxia and Hypoxic-Ischaemic Encephalopathy. Neonatology 2016, 110, 296–302. [CrossRef]

15. Irwinda, R.; Wilbovo, N.; Putri, A.S. The Concentration of Micronutrients and Heavy Metals in Maternal Serum, Placenta, and Cord Blood: A Cross-Sectional Study in Preterm Birth. J. Pregnancy 2019, 2019, 504265. [CrossRef]

16. Wang, X.M.; Tian, F.Y.; Fan, L.J.; Xie, C.B.; Niu, Z.Z.; Chen, W.Q. Comparison of DNA methylation profiles associated with spontaneous preterm birth in placenta and cord blood. BMC Med. Genom. 2019, 12, 1. [CrossRef] [PubMed]

17. Jiao, Y.; Li, X.; Liu, J. A New Approach to Cerebral Palsy Treatment: Discussion of the Effective Components of Umbilical Cord Blood and its Mechanisms of Action. Cell Transplant. 2018, 1. [CrossRef]

18. Jia, J.; Ma, B.; Wang, S.; Feng, L. Therapeutic Potential of Endothelial Colony Forming Cells Derived from Human Umbilical Cord Blood. Curr. Stem Cell Res. Ther. 2019. [CrossRef]

19. Baraniak, P.R.; McDevitt, T.C. Stem cell paracrine actions and tissue regeneration. Regen. Med. 2010, 5, 121–143. [CrossRef] [PubMed]

20. Ahn, S.Y.; Chang, Y.S.; Sung, D.K.; Sung, S.I.; Ahn, J.Y.; Park, W.S. Pivotal role of brain derived neurotrophic factor secreted by mesenchymal stem cells in severe intraventricular hemorrhage in the newborn rats. Cell Transplant. 2017, 26, 145–156. [CrossRef]

21. Feng, N.; Hao, G.; Yang, F.; Qu, F.; Zheng, H.; Liang, S.; Jin, Y. Transplantation of mesenchymal stem cells promotes the functional recovery of the central nervous system following cerebral ischemia by inhibiting myelin-associated inhibitor expression and neural apoptosis. Exp. Ther. Mol. 2016, 11, 1595–1600. [CrossRef] [PubMed]
23. Fu, Y.S.; Shih, Y.T.; Cheng, Y.C.; Min, M.Y. Transformation of human umbilical mesenchymal cells into neurons in vitro. *J. Biochem. Sci.* 2004, 11, 652–660. [CrossRef]

24. Karahuseynoglu, S.; Cinar, O.; Kilic, E.; Kara, F.; Akay, G.G.; Demiralp, D.O.; Tukun, A.; Uckan, D.; Can, A. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. *Stem Cells* 2007, 25, 319–331. [CrossRef] [PubMed]

25. Liu, L.; Eckert, M.A.; Riazifar, H.; Kang, D.K.; Agalliu, D.; Zhao, W. From Blood to the Brain: Can Systemically Transplanted Mesenchymal Stem Cells Cross the Blood-Brain Barrier? *Stem Cell Int.* 2013, 2013, 435093. [CrossRef]

26. Yagi, H.; Soto-Gutierrez, A.; Parekkadan, B.; Kitagawa, Y.; Tompkins, R.G.; Kobayashi, N.; Yarmush, M.L. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. *Cell Transplant.* 2010, 19, 667–679. [CrossRef] [PubMed]

27. Rahimzadeh, A.; Mirakabad, F.S.; Movassaghpour, A.; Shamsasenjan, K.; Kariminekoo, S.; Talebi, M.; Shekari, A.; Zeighamian, V.; Ghalbar, M.G.; Akbarzadeh, A. Biotechnological and biomedical applications of mesenchymal stem cells as a therapeutic system. *Artif. Cells Nanomed. Biotechnol.* 2016, 44, 559–570. [CrossRef] [PubMed]

28. He, L.; Zhang, H. MicroRNAs in the Migration of Mesenchymal Stem Cells. *Stem Cell Rev.* 2019, 5, 3–12. [CrossRef]

29. Wynn, R.F.; Hart, C.A.; Corradi-Perini, C.; O’Neill, L.; Evans, C.A.; Wraith, J.E.; Fairbairn, L.J.; Bellantuono, I. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. *Blood* 2004, 104, 2643–2645. [CrossRef]

30. Bhakta, S.; Hong, P.; Koc, O. The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation. *Cardiovasc. Res.* 2006, 7, 19–24. [CrossRef] [PubMed]

31. Wang, Y.; Deng, Y.; Zhou, G.Q. SDF-1alpha/CXCL12 contributes to the ‘homing’ of umbilical cord blood cells to a hypoxic-ischemic lesion in the rat brain. *J. Neurosci. Res.* 2010, 88, 1223–1233.

32. Rah, W.J.; Lee, Y.H.; Moon, J.H.; Jun, H.-J.; Kang, H.-R.; Koh, H.; Eom, H.J.; Lee, J.Y.; Lee, Y.J.; Kim, J.Y. Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: A randomized, double-blind, cross-over study. *J. Transl. Med.* 2017, 15, 16. [CrossRef] [PubMed]

33. Ramos-Cejudo, J.; Gutiérrez-Fernández, M.; Otero-Ortega, L.; Rodríguez-Frutos, B.; Fuentes, B.; Vallejo-Cremades, M.T.; Hernandez, T.N.; Cerdán, S.; Diez-Tejedor, E. Brain-derived neurotrophic factor administration mediated oligodendrocyte differentiation and myelin formation in subcortical ischemic stroke. *Stroke* 2015, 46, 221–228. [CrossRef]

34. Neubauer, V.; Wegleiter, K.; Posad, A.; Urbanek, M.; Wechselberger, K.; Kiechl-Kohlendorfer, U.; Keller, M.; Griesmaier, E. Delayed application of the haematopoietic growth factors G-CSF/SCF and FL reduces neonatal excitotoxic brain injury. *Brain Res.* 2016, 1634, 94–103. [CrossRef]

35. Li, L.; McBride, W.; Doycheva, D.; Dixon, B.J.; Krafft, P.R.; Zhang, J.H.; Tang, J. G-CSF Attenuates Neurinflammation and Stabilizes the Blood-Brain Barrier via the PI3K/Akt/GSK-3β Signaling Pathway Following Neonatal Hypoxia-Ischemia in Rats. *Exp. Neurol.* 2015, 272, 135–144. [CrossRef]

36. Vinukonda, G.; Hu, F.; Meh dizadeh, R.; Dohare, P.; Kidwai, A.; Juneja, A.; Naran, V.; Kierstead, M.; Chawla, R.; Kayton, R.; et al. Epidermal Growth Factor Preserves Myelin and Promotes Astrogliosis after Intraventricular Hemorrhage. *Glia* 2016, 64, 1987–2004. [CrossRef] [PubMed]

37. Zhen, Z.; Zhang, L.; Qu, Y.; Xiao, G.; Li, S.; Bao, S.; Lu, Q.R.; Mu, D. Mesenchymal Stem Cells Protect Against hypoxia-Ischemia Brain Damage By Enhancing Autophagy Through BDNF/mTOR Signaling Pathway. *Stem Cells* 2018, 36, 1109–1121. [CrossRef] [PubMed]

38. Wright, C.R.; Ward, A.C.; Russell, A.P. Granulocyte Colony-Stimulating Factor and Its Potential Application for Skeletal Muscle Repair and Regeneration. *Mediators Inflamm.* 2017, 7517350. [CrossRef]
40. Almlenglö, C.; Devesa, P.; Devesa, J.; Arce, V.M. GPE Promotes the Proliferation and Migration of Mouse Embryonic Neural Stem Cells and Their Progeny in Vitro. *Int. J. Mol. Sci.* 2017, 18, 1280. [CrossRef]

41. Martellucci, S.; Santacroce, C.; Santilli, F.; Piccoli, L.; Delle Monache, S.; Angelucci, A.; Misasi, R.; Sorice, M.; Mattei, V. Cellular and Molecular Mechanisms Mediated by recPrPC Involved in the Neuronal Differentiation Process of Mesenchymal Stem Cells. *Int. J. Mol. Sci.* 2019, 20, 345. [CrossRef] [PubMed]

42. Mattei, V.; Martellucci, S.; Santilli, F.; Manganelli, V.; Garofalo, T.; Candelise, N.; Caruso, A.; Sorice, M.; Scaccianoce, S.; Misasi, R. Morphine Withdrawal Modifies Prion Protein Expression in Rat Hippocampus. *PLoS ONE* 2017, 12, e0169571. [CrossRef] [PubMed]

43. Patapoutian, A.; Reichardt, L.F. Trk receptors: Mediators of neurotrophin action. *Curr. Opin. Neurobiol.* 2001, 11, 272–280. [CrossRef]

44. Fernandes, C.C.; Pinto-Duarte, A.; Ribeiro, J.A.; Sebastião, A.M. Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons. *J. Neurosci.* 2008, 28, 5611–5618. [CrossRef] [PubMed]

45. Fatemi, S.H. A Tale of Two Genes: Reelin and BDNF. In *Reelin Glycoprotein: Structure, Biology and Roles in Health and Disease*; Springer: Berlin, Germany, 2008; pp. 237–245.

46. Schneider, A.; Krüger, C.; Steigleder, T.; Weber, D.; Pitzer, C.; Laage, R.; Aronowski, J.; Maurer, M.H.; Gassler, N.; Mier, W.; et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. *J. Clin. Investig.* 2005, 115, 2083–2098. [CrossRef] [PubMed]

47. Chen, Y.; Ai, Y.; Slevinc, J.R.; Maley, B.E.; Gash, D.M. Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. *Exp. Neurrol.* 2005, 196, 87–95. [CrossRef]

48. Boku, S.; Nakagawa, S.; Takamura, N.; Kato, A.; Takebayashi, M.; Hisaoka-Nakashima, K.; Omiya, Y.; Inoue, T.; Kusumi, I. GDNF facilitates differentiation of the adult dentate gyrus-derived neural precursor cells into astrocytes via STAT3. *Biochem. Biophys. Res. Commun.* 2013, 434, 779–784. [CrossRef]

49. Ljungman, P.; Urbano-Ispizua, A.; Cavazzana-Calvo, M.; Demir, T.; Candelise, N.; Caruso, A.; Sorice, M.; Madrigal, A.; Niederwieser, D.; Passweg, J.; et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definition and current practice in Europe. *Bone Marrow Transplant.* 2006, 37, 439–449. [CrossRef]

50. Haga, H.; Yan, I.K.; Borrelli, D.A.; Matsuda, A.; Parasramka, M.; Shukla, N.; Lee, D.D.; Patel, T. Extracellular vesicles from bone marrow-derived mesenchymal stem cells protect against murine hepatic ischemia/reperfusion injury. *Liver Transpl.* 2017, 23, 791–803. [CrossRef]

51. Haga, H.; Yan, I.K.; Takahashi, K.; Matsuda, A.; Patel, T. Extracellular Vesicles from Bone Marrow-derived Mesenchymal Stem Cells Improve Survival from Lethal Hepatic Failure in Mice. *Stem Cells Transl. Med.* 2017, 6, 1262–1272. [CrossRef] [PubMed]

52. Ko, S.F.; Yip, H.K.; Zhen, Y.Y.; Lee, C.C.; Lee, C.C.; Huang, C.C.; Ng, S.H.; Lin, J.W. Adipose-derived mesenchymal stem cell exosomes suppress hepatocellular carcinoma growth in a rat model: Apparent diffusion coefficient, natural killer T-cell responses, and histopathological features. *Stem Cells Int.* 2015, 853506. [CrossRef] [PubMed]

53. Teng, X.; Chen, L.; Chen, W.; Yang, J.; Yang, Z.; Shen, Z. Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and antiinflammation. *Cell Physiol. Biochem.* 2015, 37, 2415–2424. [CrossRef] [PubMed]

54. Cui, X.; He, Z.; Liang, Z.; Chen, Z.; Wang, H.; Zhang, J. Exosomes from adipose-derived mesenchymal stem cells protect the myocardium against ischemia/reperfusion injury through Wnt/β-catenin signaling pathway. *J. Cardiovasc. Pharmacol.* 2017, 70, 225–231. [CrossRef] [PubMed]

55. Zou, X.; Zhang, G.; Cheng, Z.; Yin, D.; Du, T.; Ju, G.; Miao, S.; Liu, G.; Lu, M.; Zhu, Y. Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1. *Stem Cell Res. Ther.* 2014, 5, 40. [CrossRef] [PubMed]

56. Gatti, S.; Bruno, S.; Deregibus, M.C.; Sordi, A.; Cantaluppi, V.; Tetta, C.; Camussi, G. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. *Nephrol. Dial. Transplant.* 2011, 26, 1474–1483. [CrossRef] [PubMed]

57. Drömmschmidt, K.; Serdar, M.; Bendix, I.; Herz, J.; Bertling, F.; Prager, S.; Keller, M.; Ludwig, A.K.; Duhan, V.; Radtke, S.; et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury. *Brain Beh. Immun.* 2017, 60, 220–232. [CrossRef] [PubMed]
58. Kim, D.; Nishida, H.; An, S.Y.; Shetty, A.K.; Bartosh, T.J.; Prockop, D.J. Chromatographically isolated CD63+/CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. Proc. Natl. Acad. Sci. USA 2016, 113, 170–175. [CrossRef]

59. Xin, H.; Katakowski, M.; Wang, F.; Yang, J.J.; Zhang, Z.G.; Chopp, M. Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J. Cereb. Blood Flow Met. 2013, 33, 1711–1715. [CrossRef]

60. Jarmalaviciūtė, A.; Tunaitytis, V.; Pivoraitė, U.; Venalis, A.; Pivoriūnas, A. Exosomes from dental pulp stem cells rescue human dopaminergic neurons from 6-hydroxy-dopamine–induced apoptosis. Cytotherapy 2015, 17, 932–939. [CrossRef]

61. Katsuda, T.; Tsuchiya, R.; Kosaka, N.; Yoshioka, Y.; Takagaki, K.; Oki, K.; Takeshita, F.; Sakai, Y.; Kuroda, M.; Ochiya, T. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci. Rep. 2013, 3, 1197. [CrossRef]

62. Perets, N.; Hertz, S.; London, M.; Offen, D. Intranasal administration of exosomes derived from mesenchymal stem cells ameliorates autistic-like behaviors of BTBR mice. Mol. Autism. 2018, 9, 57. [CrossRef] [PubMed]

63. Perets, N.; Betzer, O.; Shapiro, R.; Brenstein, S.; Angel, A.; Sadan, T.; Ashery, U.; Popovtzer, R.; Offen, D. Golden Exosomes Selectively Target Brain Pathologies in Neurodegenerative and Neurodevelopmental Disorders. Nano Lett. 2019, 27. [CrossRef]

64. Ophelders, D.R.; Wolfs, T.G.; Jellema, R.K.; Zwanenburg, A.; Andriessen, P.; Delhaas, T.; Ludwig, A.K.; Radtke, S.; Peters, V.; Janssen, L.; et al. Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia. Stem Cells Transl. Med. 2016, 5, 754–763. [CrossRef] [PubMed]

65. Osier, N.; Motamedi, V.; Edwards, K.; Puccio, A.; Diaz-Arrastia, R.; Kenney, K.; Gill, J. Exosomes in Acquired Neurological Disorders: New Insights into Pathophysiology and Treatment. Mol. Neurobiol. 2018, 55, 9280–9293. [CrossRef]

66. Lin, M.H.-C.; Chung, C.-Y.; Chen, K.-T.; Yeh, J.C.; Lee, T.H.; Lee, M.H.; Lee, I.N.; Huang, W.C.; Yang, J.T. Comparison between Polybutylcyanoacrylate Nanoparticles with Either Surface-Adsorbed or Encapsulated Brain-Derived Neurotrophic Factor on the Neural Differentiation of iPSCs. Int. J. Mol. Sci. 2019, 20, 182. [CrossRef]

67. Sanchez, V.; Villalba, N.; Fiore, L.; Luzzani, C.; Miriuka, S.; Boveris, A.; Gelpi, R.J.; Brusco, A.; Poderoso, J.J. Characterization of Tunneling Nanotubes in Wharton’s jelly Mesenchymal Stem Cells. An Inter cellular Exchange of Components between Neighboring Cells. Stem Cell Rev. 2017, 13, 491–498. [CrossRef]

68. Meier, C.; Middelanis, J.; Wasielewski, B.; Neuhoff, S.; Roth-Haerer, A.; Gantert, M.; Dinse, H.R.; Dermietzel, R.; Jensen, A. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr. Res. 2006, 59, 244–249. [CrossRef] [PubMed]

69. Bae, S.H.; Kong, T.H.; Lee, H.S.; Kim, K.S.; Hong, K.S.; Chopp, M.; Kang, M.S.; Moon, J. Long-lasting paracrine effects of human cord blood cells on damaged neocortex in an animal model of cerebral palsy. Cell Transplant. 2012, 21, 2497–2515. [CrossRef]

70. Zhang, J.; Yang, C.; Chen, J.; Luo, M.; Qu, Y.; Mu, D.; Chen, Q. Umbilical cord mesenchymal stem cells and umbilical cord blood mononuclear cells improve neonatal rat memory after hypoxia-ischemia. Behav. Brain Res. 2019, 362, 56–63. [CrossRef]

71. Li, J.; Yawno, T.; Sutherland, A.E.; Gurung, S.; Paton, M.; McDonald, C.; Tiwari, A.; Pham, Y.; Castillo-Melendez, M.; Jenkin, G.; et al. Preterm umbilical cord blood derived mesenchymal stem/stromal cells protect preterm white matter brain development against hypoxia-ischemia. Exp. Neurol. 2018, 308, 120–131. [CrossRef]

72. Ko, H.R.; Ahn, S.Y.; Chang, Y.S.; Hwang, I.; Yun, T.; Sung, D.K.; Sung, S.I.; Park, W.S.; Ahn, J.Y. Human UCB-MSCs treatment upon intraventricular hemorrhage contributes to attenuate hippocampal neuron loss and circuit damage through BDNF-CREB signaling. Stem Cell Res. Ther. 2018, 9, 326. [CrossRef]

73. Boruczkowski, D.; Zdolinska-Malinowska, I. Wharton’s Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study. Stem Cells Int. 2019, 2019, 7402151. [CrossRef]

74. McDonald, C.A.; Penny, T.R.; Paton, M.C.B.; Sutherland, A.E.; Nekkanti, L.; Yawno, T.; Castillo-Melendez, M.; Fahey, M.C.; Jones, N.M.; Jenkin, G.; et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. J. Neuroinflammation 2018, 15, 47. [CrossRef]
75. Paton, M.C.B.; Allison, B.J.; Li, J.; Fahey, M.; Sutherland, A.E.; Nitsos, I.; Bischof, R.J.; Dean, J.M.; Moss, T.J.M.; Polglase, G.R.; et al. Human Umbilical Cord Blood Therapy Protects Cerebral White Matter from Systemic LPS Exposure in Preterm Fetal Sheep. *Dev. Neurosci.* 2018, 40, 258–270. [CrossRef]

76. Drobyshevsky, A.; Cotten, C.M.; Shi, Z.; Luo, K.; Jiang, R.; Derrick, M.; Tracy, E.T.; Gentry, T.; Goldberg, R.N.; Kurtzberg, J.; et al. Human Umbilical Cord Blood Cells Ameliorate Motor Deficits in Rabbits in a Cerebral Palsy Model. *Dev. Neurosci.* 2015, 37, 349–362. [CrossRef]

77. Nan, Z.; Grande, A.; Sanberg, C.D.; Sanberg, P.R.; Low, W.C. Infusion of human umbilical cord blood ameliorates neurologic deficits in rats with hemorrhagic brain injury. *Ann. N. Y. Acad. Sci.* 2005, 1049, 84–96. [CrossRef] [PubMed]

78. Lu, D.; Sanberg, P.R.; Mahmood, A.; Li, Y.; Wang, L.; Sanchez-Ramos, J.; Chopp, M. Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. *Cell Transplant.* 2002, 11, 275–281. [CrossRef]

79. Zhao, D.; Liu, L.; Chen, Q.; Wang, F.; Li, Q.; Zeng, Q.; Huang, J.; Luo, M.; Li, W.; Zheng, Y.; et al. Hypoxia with Wharton’s jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34+ cells. *Stem Cell Res. Ther.* 2018, 9, 158. [CrossRef] [PubMed]

80. Zhang, J.; Xiong, L.; Tang, W.; Tang, L.; Wang, B. Hypoxic culture enhances the expansion of rat bone marrow-derived mesenchymal stem cells via the regulatory pathways of cell division and apoptosis. *In Vitro Cell Dev. Biol. Anim.* 2018, 54, 666–676. [CrossRef] [PubMed]

81. Liu, Y.-Y.; Chiang, C.-H.; Hung, S.-C.; Chian, C.F.; Tsai, C.L.; Chen, W.C.; Zhang, H. Hypoxia-preconditioned mesenchymal stem cells ameliorate ischemia/reperfusion-induced lung injury. *PLoS ONE* 2017, 12, e0187637. [CrossRef]

82. Mas-Bargues, C.; Sanz-Ros, J.; Román-Domínguez, A.; Inglés, M.; Gimeno-Mallench, L.; El Alami, M.; Viña-Almunia, J.; Gambini, J.; Viña, J.; Borràs, C. Relevance of Oxygen Concentration in Stem Cell Culture for Regenerative Medicine. *Int. J. Mol. Sci.* 2019, 20, 1195. [CrossRef]

83. Ferreira, E.; Pasternak, J.; Bacal, N.; de Campos Guerra, J.C.; Mitte Watanabe, F. Autologous cord blood transplantation. *Bone Marrow Transplant.* 1999, 24, 1041. [CrossRef]

84. Hayani, A.; Lampeter, E.; Viswanatha, D.; Morgan, D.; Salvi, S.N. First Report of Autologous Cord Blood Transplantation in the Treatment of a Child with Leukemia. *Pediatrics* 2007, 119, 296–300. [CrossRef] [PubMed]

85. Fruchtman, S.M.; Hurlet, A.; Dracker, R.; Isola, L.; Goldman, B.; Schneider, B.L.; Emre, S. The Successful Treatment of Severe Aplastic Anemia with Autologous Cord Blood Transplantation. *Biol. Blood Marrow Transplant.* 2004, 10, 741–742. [CrossRef]

86. Schmidt, D.; Mol, A.; Odermatt, B.; Guenter, C.; Neuenschwander, S.; Zund, G.; Turina, M.; Hoerstrup, S.P. Umbilical Cord Blood Derived Endothelial Progenitor Cells for Tissue Engineering of Vascular Grafts. *Ann. Thorac. Surg.* 2004, 78, 2094–2098. [CrossRef]

87. Haller, M.J. Insulin Requirements, HbA1c, and Stimulated C-peptide following Autologous Umbilical Cord Blood Transfusion in Children with T1D. In *Immunotherapy with Cells for Type 1 Diabetes, 67th Scientific Sessions*; American Diabetes Association: Chicago, IL, USA, 22–26 June 2007; Abstract: 0313-OR.

88. Vierer, H.-L. Changes in Regulatory T Cells Following Autologous Umbilical Cord Blood Transfusion in Children with Type 1 Diabetes. In *Immunotherapy with Cells for Type 1 Diabetes, 67th Scientific Sessions*; American Diabetes Association: Chicago, IL, USA, 22–26 June 2007; Abstract 0314-OR.

89. Sharma, A.; Sane, H.; Paranjape, A.; Bhagawanani, K.; Gokulchandran, N.; Badhe, P. Autologous bone marrow mononuclear cell transplantation in Duchenne muscular dystrophy—a case report. *Am. J. Case Rep.* 2014, 28, 128–134.

90. Sharma, A.; Sane, H.; Badhe, P.; Gokulchandran, N.; Kulkarni, P.; Lohiya, M.; Biju, H.; Jacob, V.C. A Clinical Study Shows Safety and Efficacy of Autologous Bone Marrow Mononuclear Cell Therapy to Improve Quality of Life in Muscular Dystrophy Patients. *Cell Transplant.* 2013, 22, S127–S138. [CrossRef]

91. Sun, J.M.; Song, A.W.; Case, L.E.; Mikati, M.A.; Gustafson, K.E.; Simmons, R.; Goldstein, R.; Petry, J.; McLaughlin, C.; Waters-Pick, B.; et al. Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial. *Stem Cells Transl. Med.* 2017, 6, 2071–2078. [CrossRef]
92. Dawson, G.; Sun, J.M.; Davlantis, K.S.; Murias, M.; Franz, L.; Troy, J.; Simmons, R.; Sabatos-Devito, M.; Durham, R.; Kurtzberg, J. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. Stem Cells Transl. Med. 2017, 6, 1332–1339. [CrossRef] [PubMed]

93. Chez, M.; Lepage, C.; Parise, C.; Dang-Chu, A.; Hankins, A.; Carroll, M. Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. Stem Cells Transl. Med. 2018, 7, 333–341. [CrossRef] [PubMed]

94. Cotten, C.M.; Murtha, A.P.; Goldberg, R.N.; Grotegut, C.A.; Smith, P.B.; Goldstein, R.F.; Fisher, K.A.; Gustafson, K.E.; Waters-Pick, B.; Swamy, G.K.; et al. Feasibility of Autologous Cord Blood Cells for Infants with Hypoxic-Ischemic Encephalopathy. J. Pediatr. 2014, 164, 973–979. [CrossRef]

95. Yang, J.; Ren, Z.; Zhang, C.; Rao, Y.; Zhong, J.; Wang, Z.; Liu, Z.; Wei, W.; Lu, L.; Wen, J.; et al. Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study. Stem Cells Int. 2018, 5268057. [CrossRef] [PubMed]

96. Kotowski, M.; Litwinska, Z.; Klos, P.; Pius-Sadowska, E.; Zagrodnik-Ulan, E.; Ustianowski, P.; Rudnicki, J.; Machalinski, B. Autologous cord blood transfusion in preterm infants—could its humoral effect be the kez to control prematurity-related complications? A preliminary study. J. Physiol. Pharmacol. 2017, 68, 921–927.

97. Lee, Y.H.; Choi, K.V.; Moon, J.H.; Jun, H.J.; Kang, H.R.; Oh, S.I.; Kim, H.S.; Um, J.S.; Kim, M.J.; Choi, Y.Y.; et al. Safety and feasibility of counting neurological impairment by intravenous administration of autologous cord blood in cerebral palsy. J. Transl. Med. 2012, 10, 58. [CrossRef]

98. Sun, J.; Mikati, M.; Troy, J.; Gustafson, K.; Simmons, R.; Goldstein, R.; Petry, J.; McLaughlin, C.; Waters-Pick, B.; Case, L.; et al. Autologous Cord Blood Blood Infusion for the Treatment of Brain Injury in Children with Cerebral Palsy. In Proceedings of the Oral and Poster Abstracts presentation. 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL, USA, 7 December 2015. Abstract 925.

99. Englander, Z.A.; Sun, J.; Case, L.; et al. Human Umbilical Cord Blood Stem Cells: Rational Consequences of an Allogeneic Cord Blood Cell Transplant. In Proceedings of the Oral and Poster Abstracts presentation. 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL, USA, 7 December 2015. Abstract 925.

100. Xie, B.; Gu, P.; Wang, W.; Dong, C.; Zhang, L.; Zhang, J.; Liu, H.; Qiu, F.; Han, R.; Zhang, Z.; et al. Therapeutic effects of human umbilical cord mesenchymal stem cells transplantation on hypoxic ischemic encephalopathy. Am. J. Transl. Res. 2016, 8, 3241–3250.

101. Huang, L.; Zhang, C.; Gu, J.; Wu, W.; Shen, Z.; Zhou, X.; Lu, H. A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children with Cerebral Palsy. Cell Transplant. 2018, 27, 325–334. [CrossRef]

102. Bae, S.H.; Lee, H.S.; Kang, M.S.; Strupp, B.; Chopp, M.; Moon, J. The levels of pro-inflammatory factors are significantly decreased in cerebral palsy patients following an allogeneic umbilical cord blood cell transplant. Int. J. Stem Cells. 2012, 5, 31–38. [CrossRef] [PubMed]

103. Novak, I.; Walker, K.; Hunt, R.W.; Wallace, E.M.; Fahey, M.; Badawi, N. Concise Review: Stem Cell Interventions for People with Cerebral Palsy: Systematic Review with Meta-Analysis. Stem Cells Transl Med. 2016, 5, 1014–1025. [CrossRef] [PubMed]

104. Feng, M.; Lu, A.; Gao, H.; Qian, C.; Zhang, J.; Lin, T.; Zhao, Y. Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study. Stem Cells Int. 2015, 325652. [CrossRef]

105. Sun, J.M.; Grant, G.A.; McLaughlin, C.; Allison, J.; Fitzgerald, A.; Waters-Pick, B.; Kurtzberg, J. Repeated autologous umbilical cord blood blood infusions are feasible and had no acute safety issues in young babies with congenital hydrocephalus. Pediatr. Res. 2015, 8, 712–716. [CrossRef] [PubMed]

106. Arien-Zakay, H.; Lecht, S.; Nagler, A.; Lazarovici, P. Human Umbilical Cord Blood Stem Cells: Rational for Use as a Neuroprotectant in Ischemic Brain Disease. Int. J. Mol. Sci. 2010, 11, 3513–3528. [CrossRef] [PubMed]

107. Jin, H.J.; Bae, Y.K.; Kim, M.; Kwon, S.J.; Jeon, H.B.; Choi, S.J.; Kim, S.W.; Yang, Y.S.; Oh, W.; Chang, J.W. Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and Umbilical Cord Blood as Sources of Cell Therapy. Int. J. Mol. Sci. 2013, 14, 17986–18001. [CrossRef] [PubMed]

108. Nimiritsky, P.P.; Eremichev, R.Y.; Alexandrushkina, N.A.; Efimenko, A.Y.; Tkachuk, V.A.; Makarevich, P.I. Unveiling Mesenchymal Stromal Cells’ Organizing Function in Regeneration. Int. J. Mol. Sci. 2019, 20, 823. [CrossRef] [PubMed]
109. Romanov, Y.A.; Volgina, N.E.; Vtorushina, V.V.; Romanov, A.Y.; Dugina, T.N.; Kabaeva, N.V.; Sukhikh, G.T. Comparative Analysis of Secretome of Human Umbilical Cord- and Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells. *Bull. Exp. Biol. Med.* 2019, 22. [CrossRef] [PubMed]

110. Alanazi, A.; Munir, H.; Alassiri, M.; Ward, L.S.C.; McGettrick, H.M.; Nash, G.B. Comparative adhesive and migratory properties of mesenchymal stem cells from different tissues. *Biorheology* 2019, 25, 15–30. [CrossRef]

111. Meng, X.; Sun, B.; Xiao, Z. Comparison in transcriptome and cytokine profiles of mesenchymal stem cells from human umbilical cord and cord blood. *Gene* 2019, 696, 10–20. [CrossRef]

112. Lepage, S.I.M.; Lee, O.J.; Koch, T.G. Equine Cord Blood Mesenchymal Stromal Cells Have Greater Differentiation and Similar Immunosuppressive Potential to Cord Tissue Mesenchymal Stromal Cells. *Stem Cells Dev.* 2019, 28, 227–237. [CrossRef] [PubMed]

113. Lin, X.; Tan, J.Y.L.; Teh, A.L.; Lim, I.Y.; Liew, S.J.; Maclsac, J.L.; Chong, Y.S.; Gluckman, P.D.; Kober, M.S.; Cheong, C.Y.; et al. Cell type-specific DNA methylation in neonatal cord tissue and cord blood: A 850K-reference panel and comparison of cell types. *Epigenetics* 2018, 13, 941–958. [CrossRef]

114. Mehta, R.S.; Rezvani, K.; Olson, A.; Oran, B.; Hosing, C.; Shah, N.; Parmar, S.; Armitage, S.; Shpall, E.J. Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. *Front. Med.* 2015, 2, 89. [CrossRef]

115. Pineaulta, N.; Abu-Khadera, A. Advances in umbilical cord blood stem cell expansion and clinical translation. *Exp. Hematol.* 2015, 43, 498–513. [CrossRef] [PubMed]

116. Berglund, S.; Gaballa, A.; Sawaisorn, P.; Sundberg, B.; Uhlin, M. Expansion of Gammadelta T Cells from Cord Blood: A Therapeutical Possibility. *Stem Cells Int.* 2018, 8529104. [CrossRef]

117. Lund, T.C. Umbilical Cord Blood Expansion: Are We There Yet? *Biol. Blood Marrow Transplant.* 2018, 24, 1311–1312. [CrossRef] [PubMed]

118. Patterson, A.M.; Pelus, L.M. Spotlight on Glycolysis: A New Target for Cord Blood Expansion. *Cell Stem Cell.* 2018, 22, 792–793. [CrossRef]

119. Dircio-Maldonado, R.; Flores-Guzman, P.; Corral-Navarro, J.; Mondragón-García, I.; Hidalgo-Miranda, A.; Beltran-Anaya, F.O.; Cedro-Tanda, A.; Arriaga-Pizano, L.; Balvanera-Ortiz, O.; Mayani, H. Functional Integrity and Gene Expression Profiles of Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells Generated In Vitro. *Stem Cells Transl. Med.* 2018, 7, 602–614. [CrossRef] [PubMed]

120. Galindo, C.C.; Vanegas Lozano, D.M.; Camacho Rodríguez, B.; Perdomo-Arciniegas, A.M. Improved cord blood thawing procedure enhances the reproducibility and correlation between flow cytometry CD34+ cell viability and clonogenicity assays. *Cytotherapy* 2018, 20, 891–894. [CrossRef] [PubMed]

121. Raffo, D.; Perez Tito, L.; Pes, M.E.; Fernandez Sasso, D. Evaluation of DMSO dextrose as a suitable alternative for DMSO dextran in cord blood cryopreservation. *Vox Sang.* 2019, 114, 283–289. [CrossRef]

122. Amidi, F.; Rashidi, Z.; Khosravizadeh, Z.; Rashidi, Z.; Khosravizadeh, Z.; Khodamoradi, K.; Talebi, A.; Navid, S.; Abbasi, M. Antioxidant effects of quercetin in freeze-thawing process of mouse spermatogonial stem cells. *Asian Pacif. J. Rep.* 2019, 8, 7–12.

123. Kurtzberg, J.; Troy, J.D.; Bennett, E.; Belagaje, S.; Shpall, E.J.; Wiese, J.; Volpi, J.; Laskowitz, D. Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke (CoBIS): Clinical Outcomes from a Phase 1 Safety Study. *Blood* 2016, 128, 2284. [CrossRef]

124. Mozurkewich, E.L.; Berman, D.R.; Vahtrian, A.; Clinton, C.M.; Romero, V.C.; Chilimigras, J.L.; Vazquez, D.; Qualls, C.; Djuric, Z. Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines. *BMC Pregnancy Childbirth* 2018, 18, 261. [CrossRef] [PubMed]

125. Guo, L.; Wang, L.; Wang, L.; Yun-peng, S.; Zhou, J.-J.; Zhao, Z.; Li, D.-P. Resveratrol Induces Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Neuron-Like Cells. *Stem Cells Int.* 2017, 1651325. [CrossRef] [PubMed]

126. Zhang, R.; Yin, L.; Zhang, B.; Shi, H.; Sun, Y.; Ji, C.; Chen, J.; Wu, P.; Zhang, L.; Xu, W.; et al. Resveratrol improves human umbilical cord-derived mesenchymal stem cells repair for cisplatin-induced acute kidney injury. *Cell Death Dis.* 2018, 9, 965. [CrossRef]

127. Jahan, S.; Kumar, D.; Singh, S.; Kumar, V.; Srivastava, A.; Pandey, A.; Raipurohi, C.S.; Khanna, V.K.; Pant, A.B. Resveratrol Prevents the Cellular Damages Induced by Monocrotrophos via PI3K Signaling Pathway in Human Cord Blood Mesenchymal Stem Cells. *Mol. Neurobiol.* 2018, 55, 8278–8292. [CrossRef]

128. Wang, X.; Ma, S.; Yang, B.; Huang, T.; Meng, N.; Xu, L.; Xing, Q.; Zhang, Y.; Zhang, K.; Li, Q. Resveratrol promotes hUC-MSCs engraftment and neural repair in a mouse model of Alzheimer’s disease. *Behav. Brain Res.* 2018, 339, 297–304. [CrossRef] [PubMed]
129. Li, Y.; Wang, J.; Chen, G.; Feng, S.; Wang, P.; Zhu, X.; Zhang, R. Quercetin promotes the osteogenic differentiation of rat mesenchymal stem cells via mitogen-activated protein kinase signaling. *Exp. Ther. Med.* 2015, 9, 2072–2080. [CrossRef] 
130. Pang, X.-G.; Cong, Y.; Bao, N.-R.; Li, Y.G.; Zhao, J.N. Quercetin Stimulates Bone Marrow Mesenchymal Stem Cell Differentiation through an Estrogen Receptor-Mediated Pathway. *Biomed. Res. Int.* 2018, 4178021. [CrossRef] 
131. Miladpour, B.; Rasti, M.; Ovji, A.A.; Mostafavipour, Z.; Khoshdel, Z.; Noorafshan, A.; Zal, F. Quercetin potentiates transdifferentiation of bone marrow mesenchymal stem cells into the beta cells in vitro. *J. Endocrinol. Investig.* 2017, 40, 513–521. [CrossRef] 
132. Wang, X.; Wang, Y.-Y.; Zhang, L.-L.; Li, G.T.; Zhang, H.T. Combinatory effects of quercetin, a natural phenolic compound, in the differentiation of human mesenchymal stem cells (MSC) into adipocytes and osteoblasts. *J. Nutr. Biochem.* 2016, 32, 151–162. [CrossRef] [PubMed] 
133. Pinchuk, S.V.; Vasilievich, Z.; Kvacheva, B.; Volotovski, I.D. The effect of quercetin on hepatic differentiation of human adipose-derived mesenchymal stem cells. *Cell Tissue Biol.* 2016, 10, 357–364. [CrossRef] 
134. Zhou, Y.; Wu, Y.; Jiang, X.; Zhang, H.; Xia, L.; Lin, K.; Xu, Y. The Effect of Quercetin on the Osteogenic Differentiation and Angiogenic Factor Expression of Bone Marrow-Derived Mesenchymal Stem Cells. *PLoS ONE* 2015, 10, e0129605. [CrossRef] [PubMed] 
135. Kim, S.Y.; Jeong, H.C.; Hong, S.K.; Lee, M.O.; Cho, S.J.; Cha, H.J. Quercetin induced ROS production triggers mitochondrial cell death of human embryonic stem cells. *Oncotarget* 2016, 8, 64964–64973. [CrossRef] 
136. Biechonski, S.; Gourevich, D.; Rall, M.; Aqaqe, N.; Yassin, M.; Zipin-Roitman, A.; Trakhtenbrot, L.; Olender, L.; Raz, Y.; Jaffa, A.; et al. Quercetin alters the DNA damage response in human hematopoietic stem and progenitor cells via TopoII- and PI3K-dependent mechanisms synergizing in leukemogenic rearrangements. *Int. J. Cancer* 2017, 140, 864–876. [CrossRef] 
137. Baral, S.; Pariyar, R.; Kim, J.; Lee, H.S.; Seo, J. Quercetin-3-O-glucuronide promotes the proliferation and migration of neural stem cells. *Neurobiol. Aging* 2017, 52, 39–52. [CrossRef] [PubMed] 
138. Souza, C.S.; Paulsen, B.S.; Devalle, S.; Costa, S.L.; Borges, H.L.; Rehen, S.K. Commitment of human pluripotent stem cells to a neural lineage is induced by the pro-estrogenic flavonoid apigenin. *Adv. Regen. Biol.* 2015, 2. [CrossRef] 
139. Weng, Z.; Patel, A.B.; Panagiotidou, S.; Theoharides, T.C. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. *J. Allergy Clin. Immunol.* 2015, 135, 1044–1052. [CrossRef] [PubMed] 
140. Samet, I.; Villareal, M.O.; Motojima, H.; Han, J.; Sayadi, S.; Isoda, H. Olive leaf components apigenin 7-glucoside and luteolin 7-glucoside direct human hematopoietic stem cell differentiation towards erythroid lineage. *Differentiation* 2015, 89, 146–155. [CrossRef] 
141. Bugel, S.M.; Bonventre, J.A.; Tanguay, R.L. Comparative Developmental Toxicity of Flavonoids Using an Integrative Zebrafish System. *Toxicol. Sci.* 2016, 154, 55–68. [CrossRef] 
142. Buravkova, L.B.; Andreeva, E.R.; Lobanova, M.V.; Cotnezova, E.V.; Grigoriev, A. The Differential Expression of Adhesion Molecule and Extracellular Matrix Genes in Mesenchymal Stromal Cells after Interaction with Cord Blood Hematopoietic Progenitors. *Dokl. Biochem. Biophys.* 2018, 479, 69–71. [CrossRef] 
143. Hyldig, K.; Riis, S.; Pennisi, C.P.; Zachar, V.; Fink, T. Implications of Extracellular Matrix Production by Adipose Tissue-Derived Stem Cells for Development of Wound Healing Therapies. *Int. J. Mol. Sci.* 2017, 18, 1167. [CrossRef] 
144. Wharton’s Jelly Mesenchymal Stromal Cells Support the Expansion of Cord Blood-derived CD34+ Cells Mimicking a Hematopoietic Niche in a Direct Cell-cell Contact Culture System. *Cell Transplant.* 2018, 27, 117–129. [CrossRef] [PubMed] 

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).